Search results for "Enos"

showing 10 items of 1576 documents

Adjuvant denosumab in early breast-cancer

2020

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

Oncologymedicine.medical_specialtyadjuvant denosumab early-stage breast cancerBone Density Conservation AgentsAromatase Inhibitorsbusiness.industrymedicine.medical_treatmentMEDLINEantiresorptives denosumab breast cancer osteonecrosis od the jawosteonecrosis od the jawdenosumabantiresorptivesBone Density Conservation Agentsbreast cancerDenosumabOncologyInternal medicineMedicinebusinessAdjuvantmedicine.drugEarly breast cancerThe Lancet Oncology
researchProduct

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of ra…

2020

Oncologymedicine.medical_specialtylcsh:Diseases of the musculoskeletal systembusiness.industryMEDLINEEndocrine therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Bone healthlaw.inventionBreast cancermedicine.anatomical_structureDenosumabOncologyRandomized controlled triallawProstateMeta-analysisInternal medicineCommentarymedicinelcsh:RC925-935businessmedicine.drugJournal of Bone Oncology
researchProduct

Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

2019

Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, …

Oncologymedicine.medical_specialtymedicine.medical_treatmentOdontologíaReview ArticleMaxilaresTargeted therapyOncologíaImmunomodulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineOral manifestations030223 otorhinolaryngologyBonePathologicalbusiness.industryGénéralités030206 dentistryImmunotherapyCáncermedicine.diseaseCancer treatmentDenosumabSurgeryOral SurgeryOsteonecrosis of the jawbusinessAngiogenesis modulatorsInfectionmedicine.drug
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on La…

2018

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required…

Oncologyosteonecrosimedicine.medical_specialtyONJMRONJ; ONJ; denosumab; jaw; medication-related osteonecrosis of the jaw; multiple myeloma; osteonecrosis; osteonecrosis of the jaw; zoledronic acidMRONJlaw.invention03 medical and health scienceszoledronic acid0302 clinical medicinejawRandomized controlled triallawInternal medicinemedicinemedication-related osteonecrosis of the jawGeneral DentistryMultiple myelomabusiness.industryIncidence (epidemiology)Commentosteonecrosisdenosumab030206 dentistrymedicine.diseaselcsh:RK1-715multiple myelomaosteonecrosis of the jawDenosumabZoledronic acid030220 oncology & carcinogenesislcsh:DentistrybusinessOsteonecrosis of the jawmedicine.drugDentistry journal
researchProduct

Cytotoxic Action of Serratia marcescens Hemolysin on Human Epithelial Cells

1999

ABSTRACT Incubation of human epithelial cells with nanomolar concentrations of chromatographically purified Serratia marcescens hemolysin (ShlA) caused irreversible vacuolation and subsequent lysis of the cells. Vacuolation differed from vacuole formation by Helicobacter pylori VacA. Sublytic doses of ShlA led to a reversible depletion of intracellular ATP. Restoration to the initial ATP level was presumably due to the repair of the toxin damage and was inhibited by cycloheximide. Pores formed in epithelial cells and fibroblasts without disruption of the plasma membrane, and the pores appeared to be considerably smaller than those observed in artificial lipid membranes and in erythrocytes a…

OsmosisImmunologyOligosaccharidesVacuoleCycloheximideHemolysin ProteinsMicrobiologyHemolysisMicrobiologychemistry.chemical_compoundHemolysin ProteinsAdenosine TriphosphateBacterial ProteinsTumor Cells CulturedHumansPropidium iodideCytotoxicitySerratia marcescensbiologyHemolysinEpithelial CellsFibroblastsbiology.organism_classificationInfectious DiseasesEukaryotic CellschemistrySerratia marcescensMolecular and Cellular PathogenesisPotassiumParasitologyTrypan blueHeLa Cells
researchProduct

Insight into the primary mode of action of TiO2 nanoparticles on Escherichia coli in the dark.

2015

16 pages; International audience; Large-scale production and incorporation of titanium dioxide nanoparticles (NP-TiO2 ) in consumer products leads to their potential release into the environment and raises the question of their toxicity. The bactericidal mechanism of NP-TiO2 under UV light is known to involve oxidative stress due to the generation of reactive oxygen species. In the dark, several studies revealed that NP-TiO2 can exert toxicological effects. However, the mode of action of these nanoparticles is still controversial. In the present study, we used a combination of fluorescent probes to show that NP-TiO2 causes Escherichia coli membrane depolarization and loss of integrity, lead…

Osmotic stressOsmotic shock[ SDV.TOX.ECO ] Life Sciences [q-bio]/Toxicology/Ecotoxicology010501 environmental sciencesBiology[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.disease_cause01 natural sciencesBiochemistryMicrobiologyPermeability03 medical and health sciencesAdenosine TriphosphateOsmotic PressuremedicineExtracellularEscherichia coliMagnesiumMode of actionTranscriptomicsMolecular Biology030304 developmental biology0105 earth and related environmental scienceschemistry.chemical_classificationTitanium0303 health sciencesReactive oxygen speciesMicrobial ViabilityToxicityEscherichia coli ProteinsSodiumDepolarizationTitanium dioxide nanoparticlesMetabolism[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyBiochemistrychemistryBiophysicsPotassiumNanoparticles[SDV.TOX.ECO]Life Sciences [q-bio]/Toxicology/EcotoxicologyTranscriptomeOxidative stressIntracellular
researchProduct

Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective stu…

2021

BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. OBJECTIVE: To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as: study group (starting Denosumab ⩽ 12 months after AIs) and control group (&gt; 12 months). At the baseline (T0) and at 18 months (T1), we evaluated the lum…

Osteoporosisrisk of fracture0302 clinical medicineRetrospective StudieBone DensityOrthopedics and Sports Medicine030212 general & internal medicineAromataseOsteoporosis PostmenopausalbiologyBone Density Conservation AgentsAromatase InhibitorsSettore MED/34 - Medicina Fisica E RiabilitativaMedical recordRehabilitationMiddle Agedmedicine.anatomical_structureDenosumab030220 oncology & carcinogenesisOsteoporosis risk of fractures breast cancer denosumab bone healthFemaleDenosumabCase-Control StudieBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtyBone Density Conservation AgentPhysical Therapy Sports Therapy and RehabilitationBreast NeoplasmsBone health03 medical and health sciencesbreast cancerBreast cancerInternal medicinemedicineAromatase InhibitorHumansbone healthFemoral neckAgedRetrospective Studiesrisk of fracturesbusiness.industryOsteoporosiRetrospective cohort studymedicine.diseaseCase-Control Studiesbiology.proteinbusinessOsteoporotic Fractures
researchProduct

Prognostic value of the ratio between prothesis area and indexed annulus area measured by multiSlice-CT for transcatheter aortic valve implantation p…

2016

Background Postprocedural aortic regurgitations following transcatheter aortic valve implantation (TAVI) procedures remain an is- sue. Benefit of oversizing strategies to prevent them isn’t well established. We compared different level of oversizing in our cohort of con- secutive patients to address if severe oversizing compared to normal sizing had an impact on post-procedural outcomes. Methods From January 2010 to August 2013, consecutive patients were referred for TAVI with preoperative Multislice-CT (MSCT) and the procedures were achieved using Edwards Sapien® or Corevalve devices®. Retrospectively, according to pre-procedural MSCT and the valve size, pa- tients were classified into thr…

OversizingTranscatheter aortic valve implantationAortic regurgitation; Aortic valve stenosis; Multislice-CT; Oversizing; Transcatheter aortic valve implantationSymposium: Transcatheter aortic valve implantationAortic valve stenosiAortic regurgitationAortic valve stenosisMultislice-CT
researchProduct

Heterogeneity of P2-Purinoceptors in Brain Circulation

1990

The existence of P2-purinoceptors in the cerebrovascular bed was examined by testing the effects of ATP and its stable analog, α,β-methylene-ATP, on CBF in the unanesthetized goat as well as on isometric tension in isolated goat middle cerebral artery. When injected directly into the cerebral circulation, ATP increased and α,β-methylene-ATP decreased CBF. Indomethacin did not modify either of these effects. The vasoconstrictor action of α,β-methylene-ATP was reduced by nicardipine. “In vitro,” both ATP and α,β-methylene-ATP contracted the cerebral arteries at resting tone, but the analog was more potent than ATP. Repeated application of α,β-methylene-ATP as well as indomethacin significant…

P2Y receptorGoatsIndomethacinPurinergic receptorCerebral arteriesReceptors PurinergicCerebral ArteriesBiologyPharmacologyCerebral circulationAdenosine TriphosphateNeurologyVasoconstrictionCerebrovascular Circulationmedicine.arteryAnesthesiaMiddle cerebral arteryCirculatory systemmedicineAnimalsPotencyFemaleNeurology (clinical)Cardiology and Cardiovascular MedicineReceptorJournal of Cerebral Blood Flow &amp; Metabolism
researchProduct